BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25736928)

  • 1. Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.
    Pallai R; Bhaskar A; Barnett-Bernodat N; Gallo-Ebert C; Nickels JT; Rice LM
    Tumour Biol; 2015 Aug; 36(8):6067-74. PubMed ID: 25736928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.
    Pallai R; Bhaskar A; Barnett-Bernodat N; Gallo-Ebert C; Pusey M; Nickels JT; Rice LM
    Tumour Biol; 2015 Aug; 36(8):6383-90. PubMed ID: 25833693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
    Guo Z; Liu D; Su Z
    Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
    Guo Z; Liu D; Su Z
    Tumour Biol; 2015 May; 36(5):3583-9. PubMed ID: 25560487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1.
    Kim JS; Kim EJ; Oh JS; Park IC; Hwang SG
    Cancer Res; 2013 Nov; 73(22):6667-78. PubMed ID: 23983103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
    Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
    Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
    Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
    Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
    Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
    Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
    Pallai R; Bhaskar A; Sodi V; Rice LM
    Transcription; 2012; 3(6):323-35. PubMed ID: 23117818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.
    Jeong AL; Lee S; Park JS; Han S; Jang CY; Lim JS; Lee MS; Yang Y
    J Biol Chem; 2014 Jan; 289(1):28-40. PubMed ID: 24214971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
    Zhao Q; Zhao M; Parris AB; Xing Y; Yang X
    Int J Oncol; 2016 Sep; 49(3):1203-10. PubMed ID: 27574003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
    Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
    Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.
    De P; Carlson J; Leyland-Jones B; Dey N
    Oncotarget; 2014 Jul; 5(13):4581-602. PubMed ID: 25015035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin.
    Gao F; Xu T; Wang X; Zhong S; Chen S; Zhang M; Zhang X; Shen Y; Wang X; Xu C; Shen Z
    J Exp Clin Cancer Res; 2017 May; 36(1):70. PubMed ID: 28521777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIP2A inhibits PP2A in human malignancies.
    Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
    Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
    Khanna A; Böckelman C; Hemmes A; Junttila MR; Wiksten JP; Lundin M; Junnila S; Murphy DJ; Evan GI; Haglund C; Westermarck J; Ristimäki A
    J Natl Cancer Inst; 2009 Jun; 101(11):793-805. PubMed ID: 19470954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIP2A acts as a scaffold for CEP192-mediated microtubule organizing center assembly by recruiting Plk1 and aurora A during meiotic maturation.
    Wang H; Choe MH; Lee IW; Namgoong S; Kim JS; Kim NH; Oh JS
    Development; 2017 Oct; 144(20):3829-3839. PubMed ID: 28935709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.